Biotechnology

Cytiva triples single-use consumables capacity in China

* Three new manufacturing lines were successfully launched in under ten months, with an additional eight new lines planned to launch in Q3 2022. * Sustain and secure the supply chain for customers in China and the broader region.   * With the use of Fortem™ film, Cytiva helps customers speed...

2021-09-10 16:33 2508

Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine

CHENGDU, China, Sept. 9, 2021 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover) , a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that its wholly-owned subsidiary, Zhejiang Clover...

2021-09-09 19:51 1903

ABILITY Diabetes Global enrolls thousandth patient: A Cardinal Milestone Achieved

TAMPA, Fla., Sept. 9, 2021 /PRNewswire/ -- ABILITY Diabetes Global  (Randomized Comparison ofAbluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes Mellit...

2021-09-09 19:26 2195

PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation

CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- PAQ Therapeutics ("PAQ"), a biotechnology company harnessing the power of autophagy to restore health and cure disease, and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced tha...

2021-09-09 19:20 1851

China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up

HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...

2021-09-09 18:12 1885

HaemaLogiX raises $10 million to advance multiple myeloma treatments

* HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund * Funding underpins HaemaLogiX's drug development pipeline, targeting multiple myeloma - the sec...

2021-09-09 05:00 1852

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

-- First participants enrolled in Phase 1 clinical trial of combination NanoFlu™/NVX–CoV2373 vaccine with Matrix-M™ adjuvant -- Phase 1/2 study will evaluate immunogenicity and safety GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated...

2021-09-08 20:30 4761

Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41

SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces positive topline results from the U.S. Phase I trial of drug-drug interactions in healthy subjects and pharmacokinetics (PK) in patients with non-alcoholic fatty liver dise...

2021-09-08 08:30 2580

Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-09-08 08:00 7094

Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific Advisor for its CoviDTH program,Yvelise Barrios, MD, PhD, and Clinical Immuno...

2021-09-07 20:00 5715

RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

- COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to ...

2021-09-07 19:00 2281

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

- Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years - Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placeb...

2021-09-07 18:00 2346

Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer

BENGALURU, India, Sept. 7, 2021 /PRNewswire/ -- Today, Jubilant Biosys Limited announced the appointment ofGiuliano Perfetti as its Chief Executive Officer. Mr. Giuliano Perfetti joins as CEO Jubilant Bio...

2021-09-07 16:11 2636

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

-- Using NeuExcell's neuroregenerative gene therapy platform, the collaboration aims to develop an effective and safe treatment for patients suffering from Huntington's Disease. -- Spark Therapeutics' excellence in R&D and proprietary adeno-associated virus (AAV) vector gene therapy platform ma...

2021-09-07 12:00 2950

Laureates of the 2021 Global Energy Prize Announced

MOSCOW, Sept. 6, 2021 /PRNewswire/ -- The winners of the 2021 Global Energy Prize  were announced on 6th September in Kazan. The laureates were: Russian scientists Zinfer Ismagilov and Suleyman Alak...

2021-09-06 20:00 2709

The National Medical Products Administration (NMPA) issues product license for Abiraterone acetate 250 mg, Bioequivalance study conducted in India by Accutest Research Laboratories (I) Pvt. Ltd., one of the Top Indian CRO

BEIJING and MUMBAI, India, Sept. 6, 2021 /PRNewswire/ -- National Medical Products Administration  (NMPA) China, announces the approval of Abiraterone acetate 250mg ofQilu Pharmaceuticals for marketing purpose. Applicable Bioequivalance ...

2021-09-06 08:00 1968

Avidity Science Announces Agreement to Divest Lab Products & Harford Systems

WATERFORD, Wis., Sept. 4, 2021 /PRNewswire/ -- Avidity Science, a worldwide leader in life science research tools, today announces it has sold its subsidiaries of Lab Products, LLC. and Harford Systems, LLC. to Gen Cap America, Inc. ("Gen Cap"), a private equity firm focused on lower middle marke...

2021-09-04 00:00 4067

Angel Yeast Launches Patented Saccharomyces Boulardii Bld-3, a Strain of Yeast Probiotic Effective Against Diarrhea

YICHANG, China, Sept. 2, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast" or "Angel"), a listed high-tech yeast company inChina, announced its nutritional R&D team has developed a new strain of yeast probiotic,Saccharomyces boulardii Bld-3 (S. boulardii Bld-3) ...

2021-09-02 22:43 3421

Insilico Medicine Appoints the Former Chief Medical Officer of Schering Plough, Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets

SHANGHAI and NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end AI-powered drug discovery company, today announced the appointment of Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical pipeline assets. Dr. Spiegel brings over 35 years of exte...

2021-09-02 21:00 3269

CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy * The new drug applic...

2021-09-02 08:05 2867
1 ... 101102103104105106107 ... 167